Clinical trials: Neoplasms, Advanced Solid, open to volunteers
Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
- Trial name
- NCT04996121
- Testing
- XZP-5955 tablets
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)
A IIT Study of 177Lu-DOTA-SNA040
This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced…
- Conditions
- Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction), Advanced Solid Tumors (Such as Pancreatic Cancer), Advanced Solid Tumors (Such as Cholangiocarcinoma)
- Trial name
- NCT07595237
- Testing
- 177Lu-DOTA-SNA040
- Where
- China
- Volunteers
- 12 people
- Sponsor
- SmartNuclide Biopharma
Advanced or Recurrent Solid Tumors
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) .
- Trial name
- NCT06541639
- Testing
- EVM16, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Peking University
NSCLC Adenocarcinoma, Solid Tumor
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients…
- Trial name
- PARP7 (NCT07374419)
- Testing
- atamparib escalation levels, atamparib RP2D
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.
Advanced Solid Tumors
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4602 as montherapy or in combination with other anti-tumor therapies in advanced solid tumors.
- Trial name
- NCT06704828
- Testing
- SHR-4602
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
- Conditions
- Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Trial name
- eVOLVE-02 (NCT06535607)
- Testing
- Volrustomig, Cisplatin, Carboplatin
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum…
- Trial name
- NCT05205850
- Testing
- RC118-ADC
- Where
- 2 sites in China
- Volunteers
- 135 people
- Sponsor
- RemeGen Co., Ltd.
Metastatic Solid Tumors
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of SKB107 in subjects with advanced solid tumors with bone metastases.
- Trial name
- NCT07087197
- Testing
- SKB107 for injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer, Advanced/Metastatic
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors…
- Trial name
- DUO-NK-NSCLC (NCT07641023)
- Testing
- Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or…
- Conditions
- Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
- Trial name
- NCT06547840
- Testing
- MOv18 IgE
- Where
- 7 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Epsilogen Ltd
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.
- Trial name
- NCT07142980
- Testing
- HRS-7172 Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
An Exploratory Study by Fast CAR T Cells
The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy for advanced solid tumors with positive mesothelin and MUC1.Patients were screened, peripheral blood mononuclear cells (PBMC) were…
- Trial name
- NCT06327997
- Testing
- Fast CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Solid Tumor Malignancy
A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
The main purpose To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A18 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
- Trial name
- NCT06985368
- Testing
- SIBP-A18
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Shanghai Institute Of Biological Products
Solid Tumors
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
- Trial name
- NCT06066424
- Testing
- Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory or Relapsed Solid Tumors
Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
A clinical trial of QLC5508 for advanced solid tumors The goal of this clinical trial is to learn if QLC5508 can be given safely to adults with advanced solid tumors.
- Trial name
- NCT07620041
- Testing
- QLC5508 (Investigational Product / Formulation T), QLC5508 (Reference Product / Formulation R), Itraconazole
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Urothelial Carcinoma, Solid Tumor
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
This phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.
- Trial name
- NCT05965856
- Testing
- BL-B01D1, SI-B003
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumor
A Study of the ILB-3101 in Patients with Advanced Solid Tumors
ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06426680
- Testing
- ILB-3101
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Innolake Biopharm
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.